Single Dose of Tranexamic Acid and Blood Loss, in Elderly Patients With Hip Fracture
NCT ID: NCT03251469
Last Updated: 2017-08-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
200 participants
INTERVENTIONAL
2013-01-31
2018-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Does Early Administration of Tranexamic Acid Reduce Blood Loss and Perioperative Transfusion Requirement
NCT03182751
Effect of Early Administration of TXA in Adult Hip Fractures
NCT05047133
Tranexamic Acid in Intertrochanteric and Subtrochanteric Femur Fractures
NCT02580227
Early Administration Of Tranexamic Acid And Acute Blood Loss In Patients With Hip Fractures
NCT05518279
Effect of Intravenous Tranexamic Acid on Reduction of Blood Losses in Hip Fracture Patients
NCT03211286
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
intravenous tranexamic acid, 15mg/kg, preoperatively, single dose
Tranexamic Acid 15mg/kg , iv, Single Dose
Tranexamic Acid 15mg/kg , administered intravenously, preoperatively, in a single dose
Group 2
Intravenous normal saline, 100mg, preoperatively, single dose
Normal Saline, 100mg, iv, Singe dose
Normal Saline, 100mg, administered intravenously, preoperatively in single dose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tranexamic Acid 15mg/kg , iv, Single Dose
Tranexamic Acid 15mg/kg , administered intravenously, preoperatively, in a single dose
Normal Saline, 100mg, iv, Singe dose
Normal Saline, 100mg, administered intravenously, preoperatively in single dose
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Multiple fractures
* Requirement for anticoagulant therapy that could not be stopped.
* Ongoing thromboembolic event
* reduced kidney function
* malignancy,
* pathological fracture
* previous operation on the affected hip
* Active coronary artery disease (event in the past 12 months).
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National and Kapodistrian University of Athens
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Vasileios S. Nikolaou
Assistant Professor of Orthopaedics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
2nd Department of Orthopaedics
Athens, Attica, Greece
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.